Elacestrant Shows Survival Benefit in Certain ER+/HER2- Advanced Breast Cancer
Use of elacestrant (Orserdu) for patients with estrogen receptor (ER)-positive HER2-negative non-detected ESR1 mutated breast cancer prolonged progression-free survival (PFS) compared to standard-of-care (SOC) within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy. These findings from a subgroup analysis of the phase 3 EMERALD trial (NCT03778931) also demonstrated that patients with ESR1 mutations treated … [Read more…]
